Adhera Therapeutics, Inc. Appoints Andrew G. Reaume to Board of Directors
September 09, 2021 at 09:05 am EDT
Share
Adhera Therapeutics, Inc. announced the appointment of Andrew G. Reaume, Ph.D., MBA to the Company’s Board of Directors. Dr. Reaume is President and CEO of Melior Discovery, Inc., which he co-founded in 2005, building it into a robust, self-sustaining drug discovery organization and leader in pharmaceutical drug repositioning using the unique theraTRACE® platform comprised of multiplexed in vivo disease models. He subsequently spun off two sister companies, Melior Pharmaceuticals I, Inc., Melior Pharmaceuticals II, LLC, for the purpose of developing proprietary clinical stage drug candidates.
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.
ADHERA THERAPEUTICS, INC. 
